Neuro Vigor and the University of Western Australia announce drug development collaboration agreement
Neuro Vigor, a Purdue University-affiliated biotechnology company developing drugs that neutralize reactive aldehydes, announced Tuesday (Oct. 26) a collaboration agreement with the University of Western Australia to jointly develop proprietary drugs to initially target neurodegenerative diseases and pain in spinal cord injury, or SCI. Reactive aldehydes are highly toxic molecules released by cells in response to external or internal stress and trauma. They increase significantly in inflammatory, neurotraumatic and neurodegenerative disease states, damaging tissue at the cellular and molecular levels, perpetuating a destructive cycle of inflammation and oxidative stress. “This agreement jump-starts the science and technology needed to bring relief to patients
